Rxsight

Rxsight Equity Ratio

The Equity Ratio of Rxsight (RXST) as of Nov 22, 2026 is 88.41 %. In the previous year, Equity Ratio was 88.28 % — a change of 0.15% (higher).

Equity Ratio

88.41 %

YoY

0.15%

Last updated:

Equity Ratio of Rxsight is 2025 88.41 % . Equity Ratio of Rxsight was 2024 88.28 % . It decreases by 0.15% higher compared to the previous year.

The Rxsight Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
-275.84 USD
Jan 1, 2020
-295.53 USD
Jan 1, 2021
71.73 USD
Jan 1, 2022
59.87 USD
Jan 1, 2023
87.85 USD
Jan 1, 2024
88.28 USD
Jan 1, 2025
88.41 USD
The Rxsight Equity Ratio history
YEAREquity RatioYoY
88.41 %+0.15%
88.28 %+0.50%
87.85 %+46.73%
59.87 %-16.54%
71.73 %-124.27%
-295.53 %+7.14%
-275.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rxsight Stock analysis

What does Rxsight do? Rxsight Inc is an innovative company that specializes in developing innovative solutions for eye treatments. The company aims to make a positive contribution to the quality of life for patients suffering from eye problems. Rxsight Inc was founded in 2008 by Jim Taylor, who had previously worked in computer graphics at Pixar Animation Studios and was now involved in new technologies for ophthalmology. The business model of Rxsight Inc is based on the development and marketing of medical products that improve the treatment of eye diseases. The company focuses on the field of dynamic ophthalmology, which aims to improve treatment options for eye diseases by focusing on the influence of eye movements and changes in pupil size. Rxsight Inc is divided into various divisions, with an important division focusing on research and development of products that can improve the treatment of eye diseases. The company invests heavily in developing innovative products. Additionally, Rxsight Inc is also involved in the manufacturing and marketing of medical products. Rxsight Inc's products include special contact lenses that can be individually customized through precise measurement of the eye lens. These contact lenses can help patients achieve better visual quality after eye surgery. Rxsight Inc also offers certain measuring devices that are used for measuring and analyzing eye movements and pupil size. Another important product from Rxsight Inc is the "Light Adjustable Lens System," which is a system for intraocular lenses that operates based on feedback from light and energy. The system allows for an individualized process for adjusting the strength of intraocular lenses. With the "Light Adjustable Lens System," patients can achieve significantly improved visual quality after cataract surgery. Overall, Rxsight Inc has established itself as an innovative company in ophthalmology. The company focuses on research and development to provide new technologies for the treatment of eye diseases. Rxsight Inc emphasizes dynamic ophthalmology to consider the influence of eye movements and pupil size in the therapy of eye diseases. With its products, Rxsight Inc makes an important contribution to improving the visual quality of patients. Rxsight is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rxsight stock

Equity Ratio of Rxsight is 88.41 % in 2025.

Equity Ratio of Rxsight changed from 88.28 % to 88.41 %, representing a 0.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Rxsight since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Rxsight with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rxsight

All Key Metrics — Rxsight